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Abstract
Background: The correlation of S-phase kinase–associated protein 2 (Skp2) with metastasis and prognosis in
esophageal squamous cell carcinoma (ESCC) is controversial. The purpose of this study was to explore whether
there was a correlation between the expression of Skp2 evaluated by immunohistochemistry and the clinical
outcome of patients with operable ESCC, and to further determine the possible mechanism of the impact of Skp2
on survival.
Methods: Tissue microarrays that included 157 surgically resected ESCC specimens was successfully generated for
immunohistochemical evaluation. The clinical/prognostic significance of Skp2 expression was analyzed. Kaplan-Meier
analysis was used to compare the postoperative survival between groups. The prognostic impact of
clinicopathologic variables and Skp2 expression was evaluated using a Cox proportional hazards model. A cell
proliferation assay and a colony formation assay were performed in ESCC cell lines to determine the function of
Skp2 on the progression of ESCC in vitro.
Results: Skp2 expression correlated closely with the T category (p=0.035) and the pathological tumor-node-
metastasis (TNM) stage (p=0.027). High expression of Skp2 was associated with poor overall survival in resectable
ESCC (p=0.01). The multivariate Cox regression analysis demonstrated that pathological T category, pathological N
category, cell differentiation, and negative Skp2 expression were independent factors for better overall survival. In
vitro assays of ESCC cell lines demonstrated that Skp2 promoted the proliferative and colony-forming capacity of
ESCCs.
Conclusions: Negative Skp2 expression in primary resected ESCC is an independent factor for better survival. Skp2
may play a pro-proliferative role in ESCC cells.
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Background
Squamous cell carcinoma is the most common patho-
logical esophageal cancer in the East [1], and surgery is still
the best curative treatment option [2]. However, despite
having comprehensive staging tests performed to deter-
mine which patients are most likely to benefit from poten-
tially curative surgery, many patients develop tumor
recurrence after surgery, and the 5-year survival rate is
only approximately 42% [3]. The American Joint Commit-
tee on Cancer (AJCC) staging system [4] is commonly
used in the assessment of clinical outcomes in patients
with esophageal squamous cell carcinoma (ESCC). How-
ever, the system only reflects cancer progression status at
the time of diagnosis, and some patients may survive for a
long time without recurrence, whereas others with disease
in the same tumor-node-metastasis (TNM) stage may have
a more unfavorable prognosis due to tumor recurrence
and metastasis. These differences are likely attributable to
the inherent heterogeneity in the biological behavior of the
tumors. Nevertheless, in view of the complexity of cancer
progression [5-7], the availability of reliable markers is
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ging with molecular markers and other clinicopathological
parameters may be a promising method of selecting the
patients with a high risk of postoperative recurrence, for
the purpose of guiding tailored therapy.
Cell cycle regulation is critical for cell proliferation and
tumorigenesis. One of the key players regulating cell cycle
progression is the F-box protein, Skp2 (S-phase kinase–
associated protein 2) [8,9]. Recent studies reveal that the
overexpression of Skp2 is associated with the progression
of a variety of human cancers [10-14]. However, the correl-
ation of Skp2 expression with metastasis and prognosis in
ESCC is still controversial [15,16].
In this study, we first evaluated Skp2 expression in
resected ESCC by immunohistochemistry (IHC) using tis-
sue microarrays. The correlation between Skp2 expression
and clinicopathological characteristics and survival outcome
was determined. We then used ESCC cell lines to further
determine the function of Skp2 in the progression of ESCC.
Methods
Patient selection
This study was approved by the medical ethics commit-
tee of Sun Yat-sen University Cancer Center. A total of
157 primary ESCC patients who underwent complete re-
section at the Department of Thoracic Surgery at Sun
Yat-sen University Cancer Center between December
1996 and October 2004 were eligible for inclusion in the
study. All of the patients included in the study received
complete resection and were re-staged according to the
seventh edition of the AJCC Cancer Staging Manual [4].
We applied the definition of complete surgical resection
proposed by the International Association for the Study
of Lung Cancer (IASLC) Staging Committee [17].
All patients included in the analysis fit the following cri-
teria: (1) their disease was histologically defined as thoracic
squamous cell carcinoma; (2) they underwent complete re-
section; (3) they had complete information for stage group-
ing; (4) they fit into pathological AJCC stages I-III; (5) their
resections were neither preced e dn o rf o l l o w e db ya d j u v a n t
chemotherapy or radiotherapy (esophagectomy alone); and
(6) they had adequate paraffin-embedded cancer tissue
samples for use in constructing the tissue microarray.
We excluded the patients with a history of concurrent
malignant disease or other previous primary cancers and
operative deaths. Operative death is defined as death
within 30 days of the operation or any time after the op-
eration if the patient did not leave the hospital alive.
Follow-up of patients
The details of the strategy for patients’ follow-up in the
training cohort were described in our previous study [18].
April 2009 was the last time of contact for the patients.
The median time from surgery to the last time of contact
for the training cohort was 90.2 months, ranging from
60.7 to 156.1 months.
Tissue microarray construction
For uniform and simultaneous protein expression ana-
lysis of multiple tissue samples, we prepared tissue
microarrays for IHC staining. Tumor tissue samples were
collected, fixed in ethanol, and embedded in paraffin.
H&E-stained sections from a single random block from
each patient were reviewed by a senior pathologist to de-
fine representative tumor regions. For each sample, three
tissue cylinders were taken from different representative
tumor regions. Tissue cylinders with a diameter of 1 mm
were punched from selected areas of each “donor” block
using the Manual Tissue Arrayer (Beecher Instruments,
Silver Spring, MD, USA) and arrayed into a recipient
paraffin block. Serial 4 μm sections were mounted on si-
lane-coated slides for IHC staining. The final IHC stain-
ing analyses included cores from 157 ESCC cases.
IHC staining and scoring
IHC staining was performed using tissue microarray sec-
tions. The slides were deparaffinized in xylene, rehydrated
through graded alcohols to water, heated in boiled EDTA
buffer (pH 8.0) for 10 min, and cooled naturally to room
temperature. They were subsequently immersed in 3%
hydrogen peroxide solution for 10 min to remove endogen-
ous peroxidase activity, blocked with 10% goat serum at
room temperature for 30 min, and then incubated with
mouse anti-Skp2 (1:40, Invitrogen) overnight (about 16 h)
at 4°C. After being washed with PBS, the slides were incu-
bated with secondary antibody (two-step anti-rabbit/mouse
universal immunohistochemistry kit, Dako) at room
temperature for 30 min and then developed with DAB for
6.5 min. Slides were counterstained with hematoxylin.
Two independent observers who were blinded to the
clinicopathological information determined the immunor-
eactivity score (IRS) for each immunomarker. The staining
results were scored based on the following criteria: (a) per-
centage of positive tumor cells in the tumor tissue: 0 (0%),
1( 1 % –10%), 2 (11%–25%), 3 (26%–50%), 4 (51%–75%), or
5 (76%–100%); and (b) signal intensity: 0 (no staining), 1
(weak staining), 2 (moderate staining), or 3 (strong stain-
ing) [10]. IRS was calculated by multiplying the score for
the percentage of positive cells by the intensity score
(range of 0 to 15) [19]. The specimens were rescored if the
difference between the scores determined by the two
pathologists was greater than three [20]. If the conclusion
was still controversial after the specimens were rescored, a
third pathologist then intervened and worked collabora-
tively to find a consensus. The average IRS of each core
determined by the two pathologists was assigned as the
staining result for the core, and the average IRS of samples
for each case was assigned as the staining result for the
Liang et al. Journal of Translational Medicine 2012, 10:73 Page 2 of 11
http://www.translational-medicine.com/content/10/1/73patient. The patients whose staining IRS were larger than
zero were considered as positive expression of Skp2.
Cell culture
ESCC cell lines KYSE30, KYSE140, and KYSE180 were
kindly provided by Prof. Xin-Yuan Guan (Sun Yat-sen
University Cancer Center). Cells were cultured in DMEM
containing 10% fetal bovine serum at 37°C in a humidified
atmosphere containing 5% CO2.
Plasmids and siRNA transfection
Transient transfection of 50 nM of Skp2 small interfer-
ing RNA (siRNA) or scrambled siRNA was performed
using Lipofectamine 2000 (Invitrogen) according to the
manufacturer’s instructions. The sequences of the Skp2
siRNA, which were synthesized by the Ribobio Company
(Guangzhou, China) as well as the scrambled siRNA
(negative control, NC), were 5’-GGUAUCGCCUAGC
GUCUGAdTdT-3’ for the sense primer and 5’-UCA
GACGCUAGGCGAUACCdTdT-3’ for the anti-sense
primer. The sense sequence of the scrambled siRNA was
5'-UUC UCC GAA CGU GUC ACG UTT-3', of which
the anti-sense sequence was 5'-ACG UGA CAC GUU
CGG AGA ATT-3'. The plasmids of pcDNA3.1-Skp2
and pcDNA3.1 empty vector were constructed in our la-
boratory and transiently transfected into ESCC cell lines
using Lipofectamine 2000 (Invitrogen) according to the
manufacturer’s instructions [21].
Western blot assay
Cells were harvested 24 h after plasmid/siRNA transfection
and lysed in a lysis buffer containing a cocktail of protease
inhibitors. After centrifugation at 15,000×g for 15 min at
4°C, supernatants were collected, mixed with dithiothreitol
and used for western blotting. Equal amounts of protein ex-
tract were electrophoresed and then transferred to nitrocel-
lulose membranes. The membranes were blocked with 3%
non-fat milk at room temperature for 1 h, incubated with
anti-Skp2 (1:1000, Invitrogen) overnight at 4°C, and incu-
b a t e dw i t ht h es e c o n d a r ya n t i b o d ya tr o o mt e m p e r a t u r ef o r
1 h. After washing the blots, proteins were visualized by
chemiluminescence.
Cell proliferation assay
Cell proliferation was measured by a 3-[4, 5-dimethylthiazol-
2-thiazolyl]-2,5- diphenyltetrazolium bromide (MTT)
assay. ESCC cells were plated in 96-well plates at a dens-
ity of 15,000-25,000 cells/mL in triplicate. Four hours
before the desired time points, 20μLo f1 0m g / m LM T T
was added. After incubation for 4 h, the plates were
depleted and 150 μL DMSO was added. The optical
density (OD) values were determined by spectropho-
tometry (SpectraMax M5, Molecular Devices).
Colony formation assay
Briefly, 24 h after plasmid/siRNA transfection, cells were
trypsinized, resuspended as single cells, and plated in 6-well
plates with 100 cells per well. After 14 days, the colonies
were fixed with methanol and stained with crystal violet.
Colonies with more than 50 cells were counted under the
microscope. The cloning efficiency was calculated using the
following formula: colony formation efficiency (%)=(clone
number/inoculation cell number)×100%.
Statistical analysis
The SPSS statistical software package (Standard version
1 6 . 0 ;U S A ,C h i c a g o ,I L )w a su s e df o rd a t aa n a l y s i s .T h e
mean values are presented as the mean±standard devi-
ation (SD). Independent t-tests were used to compare
groups of continuous, normally distributed variables. The
Pearson chi-square test was used to determine the signifi-
cant difference between groups for dichotomous variables.
All statistical tests were two-tailed, and p<0.05 was con-
sidered statistically significant. Survival time was measured
from the date of surgery to the date of event or last follow-
up. Patients alive at the end of the study were censored for
the purpose of data analysis. Multivariate survival analysis
was performed using the Cox regression model.
Results
General patient characteristics
A total of 157 cases fit the inclusion criteria and were
included in this study. Table 1 provides the details of the
clinicopathological features of the entire cohort of
patients.
Expression of Skp2 in ESCC
In the present study, Skp2 staining of ESCC tissue
revealed immunoreactivity primarily in nuclei within
tumor cells (Figure 1). Positive Skp2 expression was
observed in 43.3% (68/157) of ESCC cases. No statisti-
cally significant correlation was observed between Skp2
expression and age, sex, tumor location, histological
grade, or N categories (Table 1), but the Skp2 expression
correlated closely with the Tcategory (p=0.035) and the
pathological AJCC stage (p=0.027).
Survival analysis
The 2-year, 3-year, and 5-year survival rates for the entire
cohort of 157 cases were 71.2%, 57.4%, and 41.5%, respect-
ively, with a median survival of 45.0 months. In patients
with negative Skp2 expression, the 2-year, 3-year, and 5-
year survival rates were 78.5%, 68.3%, and 49.9%, respect-
ively, with a median survival of 60.0 months. In patients
with positive Skp2 expression, the 2-year, 3-year, and 5-year
survival rates were 61.5%, 43.0%, and 30.4%, respectively,
with a median survival of 32.6 months. Patients with posi-
tive Skp2 expression exhibited decreased survival time
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Figure 2).
Multivariate Cox regression analysis showed that Skp2
expression, pathological T category, pathological N cat-
egory, and cell differentiation were independent factors
of overall survival (Table 2).
The effect of Skp2 on cell proliferation in ESCC cells
Because the expression of Skp2 significantly correlated
with the T category and overall survival, we proposed that
Skp2 could play a functional role in the cell proliferation
of ESCC. Hence, we performed a MTT assay to assess the
effect of Skp2 on cell proliferation in ESCC cell lines,
including KYSE30, KYSE140 and KYSE180. By transient
transfection of the pcDNA3.1-Skp2 plasmid, we observed
the overexpression of Skp2 in those cell lines by Western
Blot assays (Figure 3). Interestingly, enhanced expression
of Skp2 remarkably promoted the proliferation of ESCC
cells (the left panels of Figure 4A-C). In contrast, we uti-
lized siRNA specifically targeting Skp2 to knockdown the
protein level of Skp2 (Figure 3) and found that decreased
expression of Skp2 attenuated the proliferation of ESCC
cells (the right panels of Figure 4A-C). In summary, those
observations demonstrated the functional role of Skp2 in
promoting the proliferation of ESCC cells.
The effect of Skp2 on colony formation in ESCC cells
In addition to cell proliferation assays, we performed
colony formation experiments to further explore the
function of Skp2 in ESCC cells. Except that KYSE140
cells seldom or never formed colonies in plates (data not
shown), in both KYSE30 and KYSE180 cell lines, overex-
pression of Skp2 could dramatically enhance the poten-
tial of colony formation (the upper panels of Figure 5A
and 5C, see also the left panels of Figure 5B and 5D).
Conversely, knockdown of Skp2 led to a significant decrease
in colony-forming efficiency (the lower panels of Figure 5A
and 5C, see also the right panels of Figure 5B-5D).
Therefore, our in vitro experimental results documen-
ted that Skp2 could not only promote cell proliferation
but also facilitate colony formation in ESCC cells.
The anti-proliferative effect of proteasome inhibitor in
ESCC cells
Based on the essential role of Skp2 in the participation of
the protein ubiqutination, we further investigated the ef-
fect of proteasome inhibitor on cell proliferation and col-
ony formation in ESCC cells. We tested the cell
proliferation and colony formation with/without MG132,
one commonly used proteasome inhibitor, in ESCC cell
lines KYSE30, KYSE140 and KYSE180. With the constant
treatment of MG132 at the concentration of 10 μM, the
proliferation of all the three cell lines was significantly
aborted. However, KYSE30 cells could be highly elimi-
nated with the treatment of 1 μM MG132 as well, show-
ing much higher sensitivity to the inhibition of MG132
than KYSE140 and KYSE180 cells (Figure 6A-6C). In
the colony formation assays, both KYSE30 and KYSE180
cells were totally abolished to produce colonies in the
presence of 1 μM MG132 (Figure 6D-6F). Taken to-
gether, our data indicated that inhibition of protein ubi-
qutination could depress the cell proliferation and
colony formation in ESCC cells, suggesting the potential
application of proteasome inhibitor in the therapy for
human ESCC.
Table 1 Skp2 expression and Clinicopathological
characteristics for entire cohort of patients
Characteristics Case Skp2 Expression (%)
Negative Positive p
Age(years)
≤60 96 50 (52.1) 46 (47.9) 0.144
>60 61 39 (63.9) 22 (36.1)
Gender
Male 126 69 (54.8) 57 (45.2) 0.326
Female 31 20 (64.5) 11 (35.5)
Tumor location
Upper 20 12 (60.0) 8 (40.0) 0.796
Middle 76 41 (53.9) 35 (46.1)
Lower 61 36 (59.0) 25 (41.0)
Cell differentiation
G1 27 15 (55.6) 12 (44.4) 0.861
G2 80 47 (58.8) 33 (41.2)
G3 50 27 (54.0) 23 (46.0)
Pathological T status
T1 15 11 (73.3) 4 (26.7) 0.035
T2 42 29 (69.0) 13 (31.0)
*T3-4 100 49 (49.0) 51 (51.0)
Pathological N status
N0 87 52 (59.8) 35 (40.2) 0.438
N1 46 27 (58.7) 19 (41.3)
N2 21 9 (42.9) 12 (57.1)
N3 3 1 (33.3) 2 (66.7)
AJCC stage
I 37 28 (75.7) 9 (24.3) 0.027
II 65 34 (52.3) 31 (47.7)
III 55 27 (49.1) 28 (50.9)
Overall 157 89 (56.7) 68 (43.3) —
G1, well differentiated; G2, moderately differentiated; G3, poorly differentiated;
AJCC, American Joint Committee on Cancer; *T3: 99 cases, T4: 1 case with
negative Skp2 expression.
Liang et al. Journal of Translational Medicine 2012, 10:73 Page 4 of 11
http://www.translational-medicine.com/content/10/1/73Discussion
Skp2 was originally identified as an S-phase Kinase Cdk2/
Cyclin A-associated protein [22]. Skp2 is known as a crit-
ical component of the Skp2/SCF (Skp1-Cullin1-F-box)
complex, which is capable of inducing protein ubiquitina-
tion and subsequent proteasome-dependent degradation
[23,24]. Among the numerous substrates for degradation,
many are negative cell cycle regulators, including p27
Kip1,
p21
Cip1 and p57
Kip2 [25,26]. The ubiquitylated p27
Kip1 is
then rapidly destroyed by the proteasome, allowing the ac-
tivity of cyclin E/A-CDK2 and progression to the S phase
[27]. Overexpression of Skp2 significantly promotes the
transition from G1 phase to S phase, therefore leading to
the accelerated proliferation. In addition, Skp2 may con-
tribute to the resistance to apoptosis induction by DNA
damage agents, such as irradiation and doxorubicin [28].
Previous studies demonstrated that Skp2 was com-
monly overexpressed and associated with poor prognosis
in a variety of human cancers, including gastrointestinal
cancer [27-29], breast cancer [30,31], prostate cancer
[32,33], lung cancer [34,35] and nasopharyngeal cancer
[14,21]. However, the prognostic role of Skp2 in ESCC
has been seldom investigated and is still controversial.
Fukuchi et al. determined the Skp2 expression in a small
Figure 1 Photographs of tissue sections immunostained for Skp2, showing that Skp2 was detected in the nuclei of the esophageal
squamous carcinoma cells.( A): x100; (B): x200; (C): x400.
Figure 2 Overall survival curves for patients with positive and negative expression of Skp2.
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Skp2 might be a prognostic factor in early stage ESCC
[15]. Recently, Wang et al. reported that overexpression
of Skp2 correlated with lymph node metastasis and
advanced tumor stage in ESCC (140 cases), but unfortu-
nately, the survival prognosis was not determined in
their study [16].
In the present study, we initially showed that high ex-
pression of Skp2 in tumor cell nuclei was associated with
advanced local invasion of primary carcinoma. Moreover,
the positive expression of Skp2 in this study is indicative
of unfavorable prognosis. Multivariate Cox proportional
hazards analysis further confirmed that high Skp2 ex-
pression was an unfavorable prognostic factor independ-
ent of conventional prognostic factors, such as T
categories and N categories. These results indicated that
Skp2 could influence tumor progression of ESCC, and
Skp2 could be useful in predicting tumor recurrence for
operable ESCC. Our data showed that Skp2 expression
did not correlate with lymph node metastasis, but corre-
lated with local tumor invasion. However, Wang et al.
reported high expression of Skp2 associated with lymph
node metastasis, but not with local tumor invasion [16],
which was contrary to that of our study. The controversy
about Skp2 expression and tumor progression also exists
in colorectal carcinoma [10,27]. These controversies sug-
gest that more studies are warranted for further assess-
ment of the role of Skp2 in cancer progression. A
possible mechanism for these controversies is the hetero-
geneity of cancer. Skp2 is an essential regulator of the
cell cycle, probably playing multiple roles in carcinogen-
esis. In the present study, the case number is much lar-
ger than in previous studies [15,16]. The large number
and multivariate Cox survival analysis make our outcome
much more reliable.
Our data from in vitro experiments, including cell pro-
liferation and colony formation, provided evidence for
Skp2’s role in facilitating cancer progression, consistent
with the survival analysis results of ESCC patients. In
contrast to Wang et al.’s observation that Skp2 may
promote ESCC metastasis via inhibiting anoikis [16], our
findings exhibit a possibility that Skp2 directly speeds up
the proliferation of ESCC cells. If this is the case, our
discovery that Skp2 expression correlates with T stage
but not N stage can be explained. Based on this discov-
ery, we did not perform experiments to test the mobility
of ESCC cells in which Skp2 was overexpressed or
knocked down, since we did not found a correlation be-
tween the level of Skp2 expression and lymph node me-
tastasis in our clinicopathological data.
Our data suggests that Skp2 expression might be a
new prognostic biomarker for tumor recurrence in ESCC
patients. Therefore, the examination of Skp2 expression,
detected by IHC, could be used as an additional tool for
identifying those patients who are more likely to suffer
from recurrence after surgery. Thus, designing an opti-
mized individual adjuvant therapy strategy for resectable
ESCC patients will become possible. According to the
practice guidelines of the National Comprehensive Can-
cer Network (NCCN), adjuvant chemotherapy was not
recommended for completely resected ESCC [36]. How-
ever, many patients develop local recurrence or metasta-
sis after surgery, and the 5-year survival rate is only
about 42% [3]. For application purposes, if a patient with
operable ESCC is with high expression of Skp2, adjuvant
Table 2 Results of multivariate analyses of overall
survival by Cox regression model
Variables
RR
95% CI
p Negative Positive
Age (≤60 vs.>60) 0.950 0.639 1.413 0.799
Gender (male vs. female) 1.592 0.924 2.741 0.094
Cell differentiation (G1-2 vs. G3) 0.594 0.395 0.892 0.012
T categories (T1-2 vs. T3-4) 0.612 0.390 0.961 0.033
N categories (N0 vs.N1-3) 0.357 0.237 0.537 <0.01
Skp2 expression (negative vs. positive) 0.627 0.418 0.941 0.024
RR, relative risk; CI, confidence interval, G1, well differentiated; G2, moderately
differentiated; G3, poorly differentiated.
Figure 3 Transient overexpression or knockdown of Skp2 in
ESCC cell lines. A western blot assay was used to detect the protein
level of Skp2 36 h after transient transfection of an empty pcDNA3.1
vector (Vec), pcDNA3.1-Skp2 plasmid (Skp2), scrambled siRNA as
negative control (NC) or the siRNA specifically targeting Skp2
(siSkp2). (A) KYSE30 cell line; (B) KYSE140 cell line; (C) KYSE180 cell
line. The exogenous/endogenous Skp2 is indicated in the figure. β-
Actin was used as a loading control.
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http://www.translational-medicine.com/content/10/1/73Figure 4 Cell proliferation of ESCC cell lines after overexpression or knockdown of Skp2. MTT assays were used to measure the optical
density (OD) values of cells transfected by an empty pcDNA3.1 vector (Vec), pcDNA3.1-Skp2 plasmid (Skp2), scrambled siRNA as negative control
(NC) or the siRNA specifically targeting Skp2 (siSkp2) at the indicated time points. (A) In KYSE30 cell line. For left panel, the asterisks represent as
p=0.004 (48 h), 0.001 (72 h), and 0.002 (96 h), respectively. For right panel, the asterisk represents as p=0.001 (120 h). (B) In KYSE140 cell line. For
left panel, the asterisk represents as p=0.024 (48 h). For right panel, the asterisks represent as p=0.016 (96 h) and 0.003 (120 h), respectively. (C)I n
KYSE180 cell line. For left panel, the asterisks represent as p=0.042 (48 h), p<0.001 (72 h), and p<0.001 (96 h), respectively. For right panel, the
asterisks represent as p=0.004 (96 h) and p<0.001 (120 h), respectively. Data are represented as mean +/- SD.
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contrary, for patients with a low expression of Skp2, ob-
servation is preferred. Although further evaluation of this
strategy for clinical use will be necessary, it may help
clinicians to select the most appropriate therapies for in-
dividual ESCC patients in advance.
Despite the finding that Skp2 expression affects the
survival of patients with ESCC and the proliferation of
ESCC cells, our study has its limitations. On one hand,
there is a lack of investigation on the molecular mechan-
ism for the proliferative promotion of Skp2 in ESCC
cells. It still remains unclear which signal pathway is
involved in the Skp2-dependent regulation of ESCC pro-
liferation. On the other hand, more experiments, such as
a tumorigenesis assay in a xenograft model in vivo, are
needed to further validate the oncogenic function of
Skp2 in ESCC.
Conclusions
Skp2 expression, as determined by IHC in operable
ESCC, is a potential prognostic biomarker. The combin-
ation of AJCC staging with Skp2 expression may be use-
ful in identifying patients with increased risk of cancer
recurrence for complete resected ESCC. Furthermore,
Skp2 may play a pro-proliferative role in ESCC cells. As
a consequence, the presence of a Skp2 inhibitor might
advance ESCC therapeutic strategy. Further studies are
required to validate our results.
Figure 5 Colony formation results of ESCC cell lines after overexpression or knockdown of Skp2. Colonies were counted 2~3 weeks after
cells transfected by an empty pcDNA3.1 vector (Vec), pcDNA3.1-Skp2 plasmid (Skp2), scrambled siRNA as negative control (NC) or the siRNA
specifically targeting Skp2 (siSkp2) were planted in 6-well plates. (A) Representative photographs of colony formation in KYSE30 cell line; (B)
Statistical analysis in KYSE30 cell line. (C) Representative photographs of colony formation in KYSE180 cell line; (D) Statistical analysis in KYSE180
cell line. Data are represented as mean +/- SD. The p values are indicated in the figure.
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http://www.translational-medicine.com/content/10/1/73Figure 6 The inhibitive effect of proteasome inhibitor MG132 on cell proliferation and colony formation in ESCC cells. MTT assays were
used to assess the cell viability of cells constantly treated by MG132 at the indicated time points. The concentrations of MG132 are indicated in
the figure. (A) KYSE30 cell line; (B) KYSE140 cell line; (C) KYSE180 cell line. Colonies were counted 2~3 weeks after cells were seeded and
constantly treated by MG132 at the indicated concentrations. (D) Representative photographs of colony formation in KYSE30 cell line; (E)
Representative photographs of colony formation in KYSE180 cell line; (F) Statistical analysis in KYSE30 and KYSE180 cell lines. Data are represented
as mean +/- SD.
Liang et al. Journal of Translational Medicine 2012, 10:73 Page 9 of 11
http://www.translational-medicine.com/content/10/1/73List of abbreviations
AJCC: The American Joint Committee on Cancer; ESCC: esophageal
squamous cell carcinoma; TNM: tumor-node-metastasis; Skp2: S-phase
kinase–associated protein 2; IHC: immunohistochemistry; CT: computerized
tomography; IRS: immunoreactivity score; MTT: 3-[4,5-dimethylthiazol-2-
thiazolyl]-2,5- diphenyltetrazolium bromide; OD: optical density; SD: standard
deviation; NCCN: the National Comprehensive Cancer Network
Competing interests
The authors declare that they have no competing interests.
Acknowledgements
We thank Ms. Miao-Qing Lin for patient follow-up. This study was supported
by the Young Scientists Fund of the National Natural Science Foundation of
China (Grant No. 81000935), the 46th China Postdoctoral Science Foundation
(20090460815), Guangdong Provincial Science and Technology Planning
Foundation (2011B031800179), and the Young Teachers’ Training Program of
Sun Yat-sen University (Grant No. 11ykpy59).
Author details
1State Key Laboratory of Oncology in South China, Guangzhou 510060,
People's Republic of China.
2Department of Experimental Research, Sun
Yat-sen University Cancer Center, Guangzhou 510060, People's Republic of
China.
3Department of Medical Oncology, Sun Yat-sen University Cancer
Center, Guangzhou 510060, People's Republic of China.
4Department of
Thoracic Surgery, Sun Yat-sen University Cancer Center, No. 651, Dongfeng
East Road, 510060 Guangzhou City, Guangdong Province, People's Republic
of China.
5Department of Pathology, Sun Yat-sen University Cancer Center,
Guangzhou 510060, People's Republic of China.
Authors' contributions
YL, XH and HXY conceived the study, designed, performed and analyzed all
experiments and wrote the manuscript. Q. Cui participated in Western blot
assays. RZL and JHH participated in IHC studies. TBK, JHF, LJZ and YXZ
participated in conceiving the study. All authors read and approved the final
version of the manuscript.
Received: 11 November 2011 Accepted: 25 April 2012
Published: 25 April 2012
References
1. Younes M, Henson DE, Ertan A, Miller CC: Incidence and survival trends of
esophageal carcinoma in the United States: racial and gender
differences by histological type. Scand J Gastroenterol 2002, 37:1359–1365.
2. Law S, Wong J: What is appropriate treatment for carcinoma of the
thoracic esophagus? World J Surg 2001, 25:189–195.
3. Rice TW, Rusch VW, Apperson-Hansen C, Allen MS, Chen LQ, Hunter JG,
Kesler KA, Law S, Lerut TE, Reed CE, et al: Worldwide esophageal cancer
collaboration. Dis Esophagus 2009, 22:1–8.
4. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A III: AJCC Cancer
Staging Manual. 7th edition. New York: Springer; 2010:103–115.
5. Nguyen DX, Massague J: Genetic determinants of cancer metastasis. Nat
Rev Genet 2007, 8:341–352.
6. Chiang AC, Massague J: Molecular basis of metastasis. N Engl J Med 2008,
359:2814–2823.
7. Gupta GP, Nguyen DX, Chiang AC, Bos PD, Kim JY, Nadal C, Gomis RR,
Manova-Todorova K, Massague J: Mediators of vascular remodelling co-
opted for sequential steps in lung metastasis. Nature 2007, 446:765–770.
8. Cardozo T, Pagano M: The SCF ubiquitin ligase: insights into a molecular
machine. Nat Rev Mol Cell Biol 2004, 5:739–751.
9. Petroski MD, Deshaies RJ: Function and regulation of cullin-RING ubiquitin
ligases. Nat Rev Mol Cell Biol 2005, 6:9–20.
10. Li JQ, Wu F, Masaki T, Kubo A, Fujita J, Dixon DA, Beauchamp RD, Ishida T,
Kuriyama S, Imaida K: Correlation of Skp2 with carcinogenesis, invasion,
metastasis, and prognosis in colorectal tumors. Int J Oncol 2004, 25:87–95.
11. Radke S, Pirkmaier A, Germain D: Differential expression of the F-box
proteins Skp2 and Skp2B in breast cancer. Oncogene 2005, 24:3448–3458.
12. Lim MS, Adamson A, Lin Z, Perez-Ordonez B, Jordan RC, Tripp S, Perkins SL,
Elenitoba-Johnson KS: Expression of Skp2, a p27(Kip1) ubiquitin ligase, in
malignant lymphoma: correlation with p27(Kip1) and proliferation index.
Blood 2002, 100:2950–2956.
13. Drobnjak M, Melamed J, Taneja S, Melzer K, Wieczorek R, Levinson B,
Zeleniuch JA, Polsky D, Ferrara J, Perez SR, et al: Altered expression of p27
and Skp2 proteins in prostate cancer of African-American patients. Clin
Cancer Res 2003, 9:2613–2619.
14. Fang FM, Chien CY, Li CF, Shiu WY, Chen CH, Huang HY: Effect of S-phase
kinase-associated protein 2 expression on distant metastasis and survival
in nasopharyngeal carcinoma patients. Int J Radiat Oncol Biol Phys 2009,
73:202–207.
15. Fukuchi M, Masuda N, Nakajima M, Fukai Y, Miyazaki T, Kato H: Kuwano:
Inverse correlation between expression levels of p27 and the ubiquitin
ligase subunit Skp2 in early esophageal squamous cell carcinoma.
Anticancer Res 2004, 24:777–783.
16. Wang XC, Wu YP, Ye B, Lin DC, Feng YB, Zhang ZQ, Xu X, Han YL, Cai Y,
Dong JT: Suppression of anoikis by SKP2 amplification and
overexpression promotes metastasis of esophageal squamous cell
carcinoma. Mol Cancer Res 2009, 7:12–22.
17. Rami-Porta R, Wittekind C, Goldstraw P: Complete resection in lung cancer
surgery: proposed definition. Lung Cancer 2005, 49:25–33.
18. Yang HX, Xu Y, Fu JH, Wang JY, Lin P, Rong TH: An Evaluation of the Number
of Lymph Nodes Examined and Survival for Node-Negative Esophageal
Carcinoma: Data from China. Ann Surg Oncol 2010, 17:1901–1911.
19. Zhu ZH, Sun BY, Ma Y, Shao JY, Long H, Zhang X, Fu JH, Zhang LJ, Su XD,
Wu QL, et al: Three immunomarker support vector machines-based
prognostic classifiers for stage IB non-small-cell lung cancer. J Clin Oncol
2009, 27:1091–1099.
20. Fermento ME, Gandini NA, Lang CA, Perez JE, Maturi HV, Curino AC,
Facchinetti MM: Intracellular distribution of p300 and its differential
recruitment to aggresomes in breast cancer. Exp Mol Pathol 2010,
88:256–264.
21. Xu HM, Liang Y, Chen Q, Wu QN, Guo YM, Shen GP, Zhang RH, He ZW,
Zeng YX, Xie FY, et al: Correlation of Skp2 overexpression to prognosis of
patients with nasopharyngeal carcinoma from South China. Chin J Cancer
2011, 30:204–212.
22. Zhang H, Kobayashi R, Galaktionov K, Beach D: p19Skp1 and p45Skp2 are
essential elements of the cyclin A-CDK2 S phase kinase. Cell 1995,
82:915–925.
23. Schulman BA, Carrano AC, Jeffrey PD, Bowen Z, Kinnucan ER, Finnin MS,
Elledge SJ, Harper JW, Pagano M, Pavletich NP: Insights into SCF ubiquitin
ligases from the structure of the Skp1-Skp2 complex. Nature 2000,
408:381–386.
24. Zheng N, Schulman BA, Song L, Miller JJ, Jeffrey PD, Wang P, Chu C, Koepp
DM, Elledge SJ, Pagano M, et al: Structure of the Cul1-Rbx1-Skp1-F
boxSkp2 SCF ubiquitin ligase complex. Nature 2002, 416:703–709.
25. Gao D, Inuzuka H, Korenjak M, Tseng A, Wu T, Wan L, Kirschner M, Dyson N,
Wei W: Cdh1 regulates cell cycle through modulating the claspin/Chk1
and the Rb/E2F1 pathways. Mol Biol Cell 2009, 20:3305–3316.
26. Chan CH, Lee SW, Wang J, Lin HK: Regulation of Skp2 expression and
activity and its role in cancer progression. Scientific World Journal 2010,
10:1001–1015.
27. Shapira M, Ben-Izhak O, Linn S, Futerman B, Minkov I, Hershko DD: The
prognostic impact of the ubiquitin ligase subunits Skp2 and Cks1 in
colorectal carcinoma. Cancer 2005, 103:1336–1346.
28. Masuda TA, Inoue H, Sonoda H, Mine S, Yoshikawa Y, Nakayama K,
Nakayama K, Mori M: Clinical and biological significance of S-phase
kinase-associated protein 2 (Skp2) gene expression in gastric carcinoma:
modulation of malignant phenotype by Skp2 overexpression, possibly
via p27 proteolysis. Cancer Res 2002, 62:3819–3825.
29. Ma XM, Liu Y, Guo JW, Liu JH, Zuo LF: Relation of overexpression of S phase
kinase-associated protein 2 with reduced expression of p27 and PTEN in
human gastric carcinoma. World J Gastroenterol 2005, 11:6716–6721.
30. Sonoda H, Inoue H, Ogawa K, Utsunomiya T, Masuda TA, Mori M:
Significance of skp2 expression in primary breast cancer. Clin Cancer Res
2006, 12:1215–1220.
31. Slotky M, Shapira M, Ben-Izhak O, Linn S, Futerman B, Tsalic M, Hershko DD:
The expression of the ubiquitin ligase subunit Cks1 in human breast
cancer. Breast Cancer Res 2005, 7:R737–R744.
32. Yang G, Ayala G, De Marzo A, Tian W, Frolov A, Wheeler TM, Thompson TC,
Harper JW: Elevated Skp2 protein expression in human prostate cancer:
association with loss of the cyclin-dependent kinase inhibitor p27 and
PTEN and with reduced recurrence-free survival. Clin Cancer Res 2002,
8:3419–3426.
Liang et al. Journal of Translational Medicine 2012, 10:73 Page 10 of 11
http://www.translational-medicine.com/content/10/1/7333. Ben-Izhak O, Lahav-Baratz S, Meretyk S, Ben-Eliezer S, Sabo E, Dirnfeld M,
Cohen S, Ciechanover A: Inverse relationship between Skp2 ubiquitin
ligase and the cyclin dependent kinase inhibitor p27Kip1 in prostate
cancer. J Urol 2003, 170:241–245.
34. Osoegawa A, Yoshino I, Tanaka S, Sugio K, Kameyama T, Yamaguchi M,
Maehara Y: Regulation of p27 by S-phase kinase-associated protein 2 is
associated with aggressiveness in non-small-cell lung cancer. J Clin Oncol
2004, 22:4165–4173.
35. Zhu CQ, Blackhall FH, Pintilie M, Iyengar P, Liu N, Ho J, Chomiak T, Lau D,
Winton T, Shepherd FA, et al: Skp2 gene copy number aberrations are
common in non-small cell lung carcinoma, and its overexpression in
tumors with ras mutation is a poor prognostic marker. Clin Cancer Res
2004, 10:1984–1991.
36. National Comprehensive Cancer Network Esophageal Cancer Panel: NCCN
clinical practice guidelines in oncology, esophageal cancer. V.2.2010. [http://
www.nccn.org/professionals/physician_gls/f_guidelines.asp] (accessed 2nd
March, 2011)
doi:10.1186/1479-5876-10-73
Cite this article as: Liang et al.: Skp2 expression unfavorably impacts
survival in resectable esophageal squamous cell carcinoma. Journal of
Translational Medicine 2012 10:73.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Liang et al. Journal of Translational Medicine 2012, 10:73 Page 11 of 11
http://www.translational-medicine.com/content/10/1/73